Detail akcie Abbott Labs online

Business Summary: Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Abbott Laboratories revenues decreased 8% to $40.11B. Net income decreased 17% to $5.72B. Revenues reflect Diagnostics Products segment decrease of 40% to $9.99B, United States segment decrease of 15% to $15.45B, All other Countries segment decrease of 5% to $14.08B, Japan segment decrease of 22% to $1.51B. Net income also reflects Diagnostics Products segment income decrease of 64% to $2.43B.